• Cryptomonnaies
  • Marchés de Prédiction
  • Actualités
  • Trading Agentique
  • Articles
  • Ligues

Rechercher des Cryptomonnaies

Cryptomonnaies en tendance

CoinRithm

Entreprise

Entité légale
Bees-x Limited
Numéro de société
13308136
Constituée en
England and Wales
Siège social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm est un service d'information et de recherche exploité par Bees-x Limited. Il n'est pas autorisé par la Financial Conduct Authority (FCA) à exercer des activités réglementées, et rien sur ce site ne constitue un conseil financier.

Explorer

CryptomonnaiesMarchés de PrédictionActualitésArticlesAgent ArenaLigues

Fonctionnalités

Tableau de bordÉchange FictifTrading AgentiquePortefeuilleListe de suiviParamètres

Entreprise

À Propos de NousMethodologieConditions d'utilisationPolitique de ConfidentialitéPolitique en Matière de CookiesAvertissement

Support

Contactez le SupportFAQKit développeurDocs MCP

Réseaux

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tous droits réservés.
Disponible sur Google PlayTélécharger sur l'App Store
  • Accueil
  • MarchésMarchés de Prédiction
  • Actualités
  • Tableau de bord
  1. Marchés de Prédiction
  2. Health & Medicine
  3. When will the FDA approve Compass Pathways' COMP360 Psilocybin?
When will the FDA approve Compass Pathways' COMP360 Psilocybin?

When will the FDA approve Compass Pathways' COMP360 Psilocybin?

Health & MedicineOne-Off1a
KalshiKalshiVérifier la disponibilitéKYC requis2% de frais
Probabilité implicite actuelle
Before October 2027
Before October 2027 77%
En tête parmi 5 options
Qualite du marche

28 / 100

Faible qualité
Volume 24h

0 €

Liquidité

37,4 €

Faible liquidité
Achat / Vente

77.0% / 84.0%

Spread

9.1%

Spread large
Données du marché

Mis à jour il y a 4 minutes

24 mars 26, 14:001 oct. 27, 3:59

Tendances

Résultat24hProbabilité

Résultat choisi

Before October 202777%

Règles

If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2027, then the market resolves to Yes.

Kalshi
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Mar 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jul 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.

Marchés Associés

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3 k €
Oui: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6 k €
Oui: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7 k €
Oui: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 k €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Actifs dans ces sujets

BitcoinBTC$62,978.79+2.53%EthereumETH$1,661.11+1.78%SolanaSOL$65.42+1.74%DogecoinDOGE$0.0851+1.56%XRPXRP$1.12+0.44%BNBBNB$597.15+1.83%

Actualités Associées

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Règles

If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2027, then the market resolves to Yes.

Kalshi
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Mar 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jul 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.